With a focus on lung disease, Biodesix develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. The blood-based Biodesix Lung Reflex strategy for lung cancer patients integrates the GeneStrat and VeriStrat tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung nodule risk assessment testing strategy consisting of Nodify XL2 test and the Nodify CDT test evaluate the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
Biodesix